A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
← catalyst calendarNCT03683186 · readout ≤ 133 d
Sponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,000estimated
Sites
190
Countries
Argentina, Australia, Austria +30
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-23 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2018-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PAH
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Hypertension
- Connective Tissue Diseases
- Familial Primary Pulmonary Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension, Pulmonary
- Lung Diseases
- Respiratory Tract Disease
Intervention
- Drug: Ralinepag — also filed as APD811
Primary outcome
what the primary-completion date above is the date OFNumber of subjects with treatment-emergent adverse events [Safety and Tolerability]
measured Up to 6 years
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed